๐ญ BioIndustry
Global Biotech Industry Insights
๐ญ BioIndustryAuto
View all โBioMarin Discontinues Phase 3 ENPP1 Treatment BMN 401 After Skeletal Efficacy Failure
BioMarin Pharmaceutical (BMRN), Inozyme Pharma (former INZY)
CNO Financial to Preview Workplace Benefits and Medicare Growth Strategies
CNO Financial Group (CNO)
CARES Act Shifts FDA OTC Monograph Process to Administrative Order System
Haleon (HLN), Kenvue (KVUE), Perrigo Company (PRGO)
FDA Finalizes Rule for Additional Conditions for Nonprescription Drugs (ACNU)
Emergent BioSolutions (EBS), Perrigo Company plc (PRGO)
Revolution Medicines' Daraxoribib Demand Surges as Intellia Identifies Biomarker for Toxicity
Revolution Medicines (RVMD), Intellia Therapeutics (NTLA), Arrowhead Pharmaceuticals (ARWR), Ionis Pharmaceuticals (IONS), AstraZeneca (AZN), CSPC Pharmaceutical Group (1093.HK), Vedanta Biosciences
BioMarin Discontinues Phase 3 ENPP1 Treatment BMN 401 After Skeletal Efficacy Failure
BioMarin's (BMRN) discontinuation of Phase 3 BMN 401 significantly undermines the strategic value of the $270 million paid for the Inozyme Pharma acquisition and eliminates the 2027 launch plan. The results, which showed a significant increase in PPi but no improvement in RGI-C, rickets severity, or growth indicators, demonstrate that long-term clinical endpoints are more critical than biomarkersโฆ
CNO Financial to Preview Workplace Benefits and Medicare Growth Strategies
In the short term, the key focus is whether the annual revenue decrease of USD 30 million and the pre-tax income improvement of USD 20 million resulting from the discontinuation of the Workplace Benefits fee-based business will translate into actual margin improvements. With Medicare Supplement NAP increasing by 53% in the first quarter of 2026, the Medicare market, with approximately 68 million bโฆ
CARES Act Shifts FDA OTC Monograph Process to Administrative Order System
The administrative order system, implemented on March 27, 2020, enables faster updates to the safety and labeling standards for over 80 therapeutic categories and approximately 800 active ingredients, turning regulatory responsiveness into a competitive advantage. Haleon (HLN)'s Advil, Kenvue (KVUE)'s Tylenol, and Perrigo Company (PRGO)'s private label analgesics, all in the Marketed stage, are afโฆ
FDA Finalizes Rule for Additional Conditions for Nonprescription Drugs (ACNU)
From an investor's perspective, ACNU represents a new lifecycle management pathway for connecting chronic disease prescriptions to the USD 44.3 billion U.S. OTC market in 2024, but the absence of currently approved products means that the first applicant faces significant implementation risk. Researchers must design self-selection questionnaires, actual use, and condition failure data in additionโฆ
Revolution Medicines' Daraxoribib Demand Surges as Intellia Identifies Biomarker for Toxicity
Daraxoribib's Phase 3 results, with a median overall survival of 13.2 months, provide a strong basis for reshaping the second-line treatment standard in the USD$3.82 billion pancreatic cancer market, and the demand from over 2,000 patients serves as a leading indicator of early market penetration. Intellia's HLA-C*05:01 screening not only enables the re-start of its Phase 3 trial but also influencโฆ
Samsung Bioepis' Epysqli Receives EU Approval as a Soliris Biosimilar
This approval marks Samsung Bioepis' launch of Epysqli, a C5 inhibitor that completed Phase 3 trials, into the $3.145 billion Soliris market in 2023. In the short term, it will lower prices in European tenders along with Amgen (AMGN)'s Bekemv, putting pressure on AstraZeneca (AZN)'s Soliris sales and the profitability of its rare disease franchise. In the medium to long term, it will broaden accesโฆ
FDA Grants Emergency Use Authorization for Elanco's CLiK Extra for Screwworm Prevention
The FDA's EUA on August 7, 2026, allows Elanco Animal Health Incorporated (ELAN) to introduce its existing CLiK Extra product to the U.S. market for the prevention of NWS in sheep, goats, cattle, and pigs. The USDA estimates that an NWS outbreak at the level seen in Texas in 1976 would result in total economic losses for the state of $1.4 billion in 2016 dollars, indicating that the demand for conโฆ
Latigo to Accelerate Phase 3 Trial of LTG-001 with $345.6 Million IPO
The $345.6 million IPO provides capital to conduct Latigo's Phase 3 trial in bunion surgery patients and a 400-patient safety Phase 3 trial in the second half of 2026, with the data expected in the second half of 2027 serving as a key value inflection point. While the high-dose LTG-001 achieved a SPID48 of 62.1 points and a p-value of less than 0.001 compared to placebo in the Phase 2b trial, demoโฆ
Tarsus Acquires Alkeus for $800 Million, Securing Phase 3 Program for Gildeuretinol
From an investor perspective, the profitability of a transaction involving up to $800 million plus separate royalties hinges on the reproducibility of the lesion growth inhibition observed in the 230-patient Phase 3 NORTHSTAR trial and the expected primary completion date of October 2029. Belite Bio (BLTE)'s tinlarebant, which reduced lesion growth by 36% in Phase 3 with a p-value of 0.0033 and isโฆ
BioOra and Malaghan Institute Launch Phase 2 Trial for Atla-cel, a CD19 CAR-T Therapy
ENABLE-2 is a Phase 2 trial with 60 patients, designed to support registration, and the key to the asset's value lies in replicating the 52% complete response rate at 3 months and the absence of severe CRS/ICANS observed in the Phase 1 trial. With Yescarta, Breyanzi, and Kymriah already approved, the key differentiators will be durability of response, neurotoxicity, manufacturing success rate, andโฆ
Merck's Nemtabrutinib Phase 3 Trial Aims to Challenge First-Line BTK Inhibitors in CLL
A successful Phase 3 trial involving approximately 1,200 patients will allow Merck & Co. (MRK) to secure a first-line treatment entry in the global CLL market, which is valued at USD 7.0 billion in 2024. The direct comparison to marketed BTK inhibitors, ibrutinib and Calquence, means that PFS superiority, as well as atrial fibrillation, bleeding, and infection safety, will be key factors in adoptiโฆ
NCI's Long-Term Follow-Up of the Vorinostat and Azacitidine Combination in Phase 1/2 MDS/AML Trial
This study generated initial signals of CR 45% and CRi 9% in Phase 1/2, but subsequent randomized AML studies involving 259 patients showed that ORR and OS improvements were not significant (p=0.84 and p=0.32, respectively), highlighting the limitations of single-arm data. From an investment perspective, despite targeting the USD 3.5 billion AML market and the USD 2.4 billion MDS market, the additโฆ